Find A Physician

Return to Dr. Kara Kelly Named Chair of Hodgkin Lymphoma Committee Overview

More on Dr. Kara Kelly Named Chair of Hodgkin Lymphoma Committee

Research and Clinical Trials

Return to Dr. Kara Kelly Named Chair of Hodgkin Lymphoma Committee Overview

More on Dr. Kara Kelly Named Chair of Hodgkin Lymphoma Committee

Dr. Kara Kelly Named Chair of Hodgkin Lymphoma Committee

New York (Sep 1, 2011)

Kara Kelly, M.D., Medical Director of the Integrative Therapies Program for Children with Cancer at the Herbert Irving Child & Adolescent Oncology Center, NewYork-Presbyterian/Morgan Stanley Children's Hospital, has been named Chair of the Hodgkin Lymphoma Committee of the Children's Oncology Group (COG).

Kara Kelly, M.D.
Kara Kelly, M.D.

An internationally recognized leader in pediatric cancer and complementary medicine, Dr. Kelly assumed her new role within the COG in March 2011. Dr. Kelly, who is Associate Professor of Clinical Pediatrics at Columbia University College of Physicians and Surgeons, was selected by Dr. Peter Adamson, Chair of COG, to lead the committee responsible for clinical trials of treatments for Hodgkin lymphoma in children and adolescents.

Children's Oncology Group

The Children's Oncology Group unites more than 5,000 experts in childhood cancer at leading children's hospitals, universities, and cancer centers across North America, Australia, New Zealand, and Europe in the fight against childhood cancer. Today, more than 90 percent of the 12,500 children diagnosed with cancer each year in the United States are treated at COG institutions, with the Herbert Irving Child & Adolescent Oncology Center at Columbia University Medical Center among the largest such centers in the world.

About Dr. Kara Kelly

Dr. Kelly graduated from Brown University and received an M.D. degree from the State University at Buffalo. She completed her internship, residency, and fellowship at The Children's Hospital of Philadelphia with an additional fellowship at the Hospital for Sick Children in London. She has been at Columbia University since 1996. Throughout her career at Columbia, Dr. Kelly has been on the forefront of innovative research and clinical programming. As Medical Director of the Integrative Therapies Program for Children with Cancer, Dr. Kelly and her team were the first clinicians in the country to mainstream complementary and alternative medical therapies into a pediatric oncology setting. Invited to speak all over the world on childhood cancer, Dr. Kelly is also the author and co-author of over 100 articles and medical abstracts.

Recent Research

Separately, a recent clinical trial led by Dr. Kelly as Principal Investigator has identified a chemotherapy program that produces a 97 percent five-year survival rate, the highest rate ever reported – while potentially reducing the odds of long-term side effects in most patients. The findings of the multi-center trial were reported in the March 2011 issue of Blood, one of the medical profession's most prestigious journals of oncology/hematology. Click here to read the entire article.

Clinical Trial for Hodgkin Lymphoma

Hodgkin lymphoma is one of the most treatable childhood cancers, with a five-year survival rate of approximately 90 percent. However, the chemotherapy and radiation aggressively dispensed to save patient's lives sadly increases the possibility of other cancers later in life. The trial led by Dr. Kelly for COG tested the idea that intense treatment, followed by less aggressive treatment for rapid responders, would lead to success while reducing long-term side effects. In the study, all patients were treated first with BEACOPP, a high-dose regimen of seven different cancer drugs that has shown success in adult Hodgkin patients. The study showed remarkable results after reducing treatment in three quarters of the study patients. The hope is BEACOPP will be considered for the pediatric population.

As the new chair of the Hodgkin Lymphoma Committee of COG, Dr. Kelly is also leading a follow-up study to see if more elements of the BEACOPP regimen can be eliminated or reduced to further diminish the odds of long-term side effects.

A Resource for Families

Dr. Kelly has co-authored a new book with her colleague, Elena Ladas, who is Director of the Integrative Therapy Program for Children with Cancer: Integrative Strategies for Cancer Patients: A Practical Resource for Managing the Side Effects of Cancer Therapy. To learn more about the book, please click here.

  • Bookmark
  • Print

    Find a Doctor

Click the button above or call
1 877 NYP WELL


eNewsletters

Newsroom



Top of page